Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment of Upper Facial Lines

BACKGROUND Botulinum toxins are the treatment of choice for wrinkles in the upper third of the face. OBJECTIVE The purpose of this study was to evaluate the efficacy, safety, and subject satisfaction of abobotulinumtoxinA (ABO) for treatment of upper facial lines. MATERIALS AND METHODS Subjects aged 35 to 50 years with moderate-to-severe upper facial lines were included in this study. Subjects received a maximum of 125 s.U. ABO in at least 2 indications with optional touch-up after 2 weeks. Assessments included wrinkle severity, global aesthetic improvement, subject satisfaction, and adverse events (AEs) 1, 3, and 6 months after treatment. RESULTS At Month 1, 100, 94, and 93% of subjects were responders in dynamic glabellar, lateral canthal, and forehead lines, respectively. All subjects were improved 1 month after treatment, and the majority of the subjects were still improved after 6 months. After treatment, most subjects were satisfied with the appearance of their face, felt better about themselves, and agreed that the treatment made them look the way they feel. Seven subjects (22%) had 8 ABO-related AEs (mild–moderate); headache was most commonly reported (9%). CONCLUSION AbobotulinumtoxinA effectively treated upper facial lines, with high patient satisfaction. Treatment was generally well-tolerated. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Address correspondence and reprint requests to: Doris Hexsel, MD, Brazilian Center for Studies in Dermatology, Rua D. Pedro II 1592, 90550-141 Porto Alegre, RS, Brazil, or e-mail: doris@hexsel.com.br Galderma funded the study and provided the study products. Interim results from this study were previously presented as abstracts/posters at the International Master Course on Aging Science (IMCAS) Annual World Congress; January 26–29, 2017; Paris, France, and at the 15th Aesthetic and Anti-aging Medicine World Congress (AMWC); April 6–8, 2017; Monte Carlo, Monaco. D. Hexsel is a consultant for Galderma and Merz. P. Hedén is a consultant for Allergan, Teoxane, and Galderma. C. Skoglund and C. Edwartz are employed by Galderma. D. Rees of Zenith Healthcare Communications Ltd., provided medical writing assistance, funded by Galderma. P. Kestemont is a consultant for Allergan, Filorga, Galderma, Teoxane, Universkin, and Vivacy. The remaining authors have indicated no significant interest with commercial supporters. © 2018 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2NCGURp